New Risk • Jul 26
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 84% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (84% net debt to equity). Large one-off items impacting financial results. Reported Earnings • Jul 24
Second quarter 2026 earnings released: EPS: Mex$1.99 (vs Mex$0.27 loss in 2Q 2025) Second quarter 2026 results: EPS: Mex$1.99 (up from Mex$0.27 loss in 2Q 2025). Revenue: Mex$37.5b (up 14% from 2Q 2025). Net income: Mex$4.14b (up Mex$4.72b from 2Q 2025). Profit margin: 11% (up from net loss in 2Q 2025). Revenue is forecast to stay flat during the next 3 years compared to a 3.6% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Duyuru • Jul 03
ALPEK, S.A.B. de C.V. to Report Q2, 2026 Results on Jul 22, 2026 ALPEK, S.A.B. de C.V. announced that they will report Q2, 2026 results After-Market on Jul 22, 2026 Duyuru • Mar 25
ALPEK, S.A.B. de C.V. to Report Q1, 2026 Results on Apr 22, 2026 ALPEK, S.A.B. de C.V. announced that they will report Q1, 2026 results After-Market on Apr 22, 2026 Duyuru • Feb 13
ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 03, 2026 ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 03, 2026. Location: 1111 gomez morin avenue, carrizalejo neighborhood, san pedro garza garcia, nuevo leon, monterrey Mexico Duyuru • Jan 14
ALPEK, S.A.B. de C.V. to Report Q4, 2025 Results on Feb 10, 2026 ALPEK, S.A.B. de C.V. announced that they will report Q4, 2025 results on Feb 10, 2026 Duyuru • Sep 26
ALPEK, S.A.B. de C.V. to Report Q3, 2025 Results on Oct 21, 2025 ALPEK, S.A.B. de C.V. announced that they will report Q3, 2025 results on Oct 21, 2025 Duyuru • Jun 24
ALPEK, S.A.B. de C.V. to Report Q2, 2025 Results on Jul 22, 2025 ALPEK, S.A.B. de C.V. announced that they will report Q2, 2025 results on Jul 22, 2025 Duyuru • Apr 03
ALPEK, S.A.B. de C.V. to Report Q1, 2025 Results on Apr 22, 2025 ALPEK, S.A.B. de C.V. announced that they will report Q1, 2025 results on Apr 22, 2025 Duyuru • Mar 05
ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 20, 2025 ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 20, 2025. Location: ave gomez morin 1111 south, carrizalejo neighborhood, san pedro garza garcia, nuevo leon, monterrey Mexico Duyuru • Jan 31
ALPEK, S.A.B. de C.V. to Report Q4, 2024 Results on Feb 18, 2025 ALPEK, S.A.B. de C.V. announced that they will report Q4, 2024 results on Feb 18, 2025 Reported Earnings • Oct 29
Third quarter 2024 earnings released: EPS: Mex$0.23 (vs Mex$0.21 loss in 3Q 2023) Third quarter 2024 results: EPS: Mex$0.23 (up from Mex$0.21 loss in 3Q 2023). Revenue: Mex$37.2b (up 11% from 3Q 2023). Net income: Mex$483.0m (up Mex$922.8m from 3Q 2023). Profit margin: 1.3% (up from net loss in 3Q 2023). Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance. Duyuru • Oct 15
ALPEK, S.A.B. de C.V. to Report Q3, 2024 Results on Oct 28, 2024 ALPEK, S.A.B. de C.V. announced that they will report Q3, 2024 results After-Market on Oct 28, 2024 Buy Or Sell Opportunity • Oct 07
Now 22% overvalued Over the last 90 days, the stock has fallen 3.8% to €0.64. The fair value is estimated to be €0.52, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Sep 13
Now 26% overvalued Over the last 90 days, the stock has fallen 3.1% to €0.63. The fair value is estimated to be €0.50, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Aug 28
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 28% to €0.54. The fair value is estimated to be €0.68, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Buy Or Sell Opportunity • Aug 03
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 18% to €0.57. The fair value is estimated to be €0.72, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Reported Earnings • Jul 26
Second quarter 2024 earnings released: EPS: Mex$0.10 (vs Mex$0.26 in 2Q 2023) Second quarter 2024 results: EPS: Mex$0.10 (down from Mex$0.26 in 2Q 2023). Revenue: Mex$33.0b (down 9.0% from 2Q 2023). Net income: Mex$216.0m (down 61% from 2Q 2023). Profit margin: 0.7% (down from 1.5% in 2Q 2023). Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 4.4% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance. Duyuru • Jul 10
ALPEK, S.A.B. de C.V. to Report Q2, 2024 Results on Jul 24, 2024 ALPEK, S.A.B. de C.V. announced that they will report Q2, 2024 results on Jul 24, 2024 Reported Earnings • Apr 24
First quarter 2024 earnings released: EPS: Mex$0.065 (vs Mex$0.043 loss in 1Q 2023) First quarter 2024 results: EPS: Mex$0.065 (up from Mex$0.043 loss in 1Q 2023). Revenue: Mex$32.3b (down 16% from 1Q 2023). Net income: Mex$137.0m (up Mex$228.4m from 1Q 2023). Profit margin: 0.4% (up from net loss in 1Q 2023). Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. Duyuru • Apr 09
ALPEK, S.A.B. de C.V. to Report Q1, 2024 Results on Apr 23, 2024 ALPEK, S.A.B. de C.V. announced that they will report Q1, 2024 results on Apr 23, 2024 New Risk • Feb 23
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 2.9x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risk Dividend is not well covered by earnings (371% payout ratio). Buy Or Sell Opportunity • Feb 21
Now 29% overvalued Over the last 90 days, the stock has fallen 11% to €0.62. The fair value is estimated to be €0.48, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has grown by 5.0%. Revenue is forecast to decline by 8.4% in 2 years. Earnings are forecast to grow by 381% in the next 2 years. Duyuru • Feb 16
ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 06, 2024 ALPEK, S.A.B. de C.V., Annual General Meeting, Mar 06, 2024, at 10:15 Central Standard Time. Location: Avenida Gómez Morín No. 1111 Sur, Colonia Carrizalejo, San Pedro Garza García, Nuevo León Nuevo Leon Mexico Agenda: To consider the Presentation and, as the case may be, approval of the reports referred to in Article 28, section IV, of the Mexican Securities Market Law, relating to the fiscal year 2023; to Proposal on the allocation of the income statement for the fiscal year 2023, which includes the determination of the maximum amount of funds that may be used to purchase the Company’s own stock; to Election of the members of the Board of Directors, as well as the Chairman of the Audit and Corporate Governance Committee; determination of their compensation and related agreements; to Appointment of delegates; to Reading and, as the case may be, approval of the Minutes of the Meeting; and to consider other matters if any. Duyuru • Jan 31
ALPEK, S.A.B. de C.V. to Report Q4, 2023 Results on Feb 20, 2024 ALPEK, S.A.B. de C.V. announced that they will report Q4, 2023 results on Feb 20, 2024 Buy Or Sell Opportunity • Jan 24
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 2.5% to €0.58. The fair value is estimated to be €0.73, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 19% over the last 3 years. Earnings per share has grown by 5.0%. Revenue is forecast to decline by 7.3% in 2 years. Earnings are forecast to grow by 411% in the next 2 years. New Risk • Nov 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (57% net debt to equity). Dividend is not well covered by earnings (371% payout ratio). Share price has been volatile over the past 3 months (6.6% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.5% net profit margin). Reported Earnings • Oct 25
Third quarter 2023 earnings released: Mex$0.21 loss per share (vs Mex$1.07 profit in 3Q 2022) Third quarter 2023 results: Mex$0.21 loss per share (down from Mex$1.07 profit in 3Q 2022). Revenue: Mex$33.4b (down 44% from 3Q 2022). Net loss: Mex$439.0m (down 120% from profit in 3Q 2022). Revenue is forecast to grow 1.9% p.a. on average during the next 3 years, compared to a 1.9% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 2% per year. Duyuru • Oct 10
ALPEK, S.A.B. de C.V. to Report Q3, 2023 Results on Oct 23, 2023 ALPEK, S.A.B. de C.V. announced that they will report Q3, 2023 results on Oct 23, 2023 New Risk • Aug 14
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.9% Last year net profit margin: 7.1% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks High level of debt (63% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (1.9% net profit margin). Duyuru • Jul 07
ALPEK, S.A.B. de C.V. to Report Q2, 2023 Results on Jul 26, 2023 ALPEK, S.A.B. de C.V. announced that they will report Q2, 2023 results at 11:30 AM, Central Standard Time on Jul 26, 2023 Reported Earnings • Apr 28
First quarter 2023 earnings released: Mex$0.043 loss per share (vs Mex$2.23 profit in 1Q 2022) First quarter 2023 results: Mex$0.043 loss per share (down from Mex$2.23 profit in 1Q 2022). Revenue: Mex$38.6b (down 19% from 1Q 2022). Net loss: Mex$91.0m (down 102% from profit in 1Q 2022). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 1.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 22
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €1.21, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 14x in the Chemicals industry in Germany. Total returns to shareholders of 135% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €1.53 per share. Reported Earnings • Feb 18
Full year 2022 earnings released: EPS: Mex$6.52 (vs Mex$3.67 in FY 2021) Full year 2022 results: EPS: Mex$6.52 (up from Mex$3.67 in FY 2021). Revenue: Mex$212.4b (up 36% from FY 2021). Net income: Mex$13.7b (up 77% from FY 2021). Profit margin: 6.5% (up from 5.0% in FY 2021). The increase in margin was driven by higher revenue. Revenue is expected to decline by 7.4% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to grow by 1.5%. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Duyuru • Feb 01
ALPEK, S.A.B. de C.V. to Report Q4, 2022 Results on Feb 15, 2023 ALPEK, S.A.B. de C.V. announced that they will report Q4, 2022 results on Feb 15, 2023 Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 8 highly experienced directors. Independent Director Jaime Zabludovsky Kuper was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 22
Third quarter 2022 earnings released: EPS: Mex$1.07 (vs Mex$1.05 in 3Q 2021) Third quarter 2022 results: EPS: Mex$1.07 (up from Mex$1.05 in 3Q 2021). Revenue: Mex$59.8b (up 44% from 3Q 2021). Net income: Mex$2.25b (up 1.2% from 3Q 2021). Profit margin: 3.8% (down from 5.3% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to decline by 4.7% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Duyuru • Oct 04
ALPEK, S.A.B. de C.V. to Report Q3, 2022 Results on Oct 20, 2022 ALPEK, S.A.B. de C.V. announced that they will report Q3, 2022 results on Oct 20, 2022 Reported Earnings • Jul 23
Second quarter 2022 earnings released: EPS: Mex$2.87 (vs Mex$1.18 in 2Q 2021) Second quarter 2022 results: EPS: Mex$2.87 (up from Mex$1.18 in 2Q 2021). Revenue: Mex$56.4b (up 52% from 2Q 2021). Net income: Mex$6.06b (up 144% from 2Q 2021). Profit margin: 11% (up from 6.7% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is expected to shrink by 2.8% compared to a 7.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 7% per year. Duyuru • Jul 01
ALPEK, S.A.B. de C.V. to Report Q2, 2022 Results on Jul 20, 2022 ALPEK, S.A.B. de C.V. announced that they will report Q2, 2022 results on Jul 20, 2022 Duyuru • Jun 02
ALPEK, S.A.B. de C.V. (BMV:ALPEK A) completed the acquisition of OCTAL Holding SAOC from bank muscat SAOG (MSM:BKMB) and others. ALPEK, S.A.B. de C.V. (BMV:ALPEK A) agreed to acquire OCTAL Holding SAOC from bank muscat SAOG (MSM:BKMB) and others for $620 million on February 1, 2022. Alpek will purchase 100% of Octal’s shares for U.S. $620 million on a debt-free basis. Financing for the acquisition will be secured through cash on the Company’s balance sheet, free cash flow generated from existing businesses and dedicated bank loans. The transaction is subject to customary conditions to closing, including the approval of relevant regulatory authorities. As of April 26, 2022, regulatory approval was received. The transaction is expected to close in the first half of 2022. As of April 26, 2022, the transaction is expected to close by the end of second quarter of 2022. The deal would have an immediately accretive and material impact on EBITDA of an estimated U.S. $135 million before synergies, based on Octal’s rolling 12-month EBITDA through September 30, 2021. J.P. Morgan acted as exclusive financial advisor to OCTAL and Christopher Lester and Nomaan A. Raja of Latham & Watkins LLP were legal advisors to OCTAL. HSBC Holdings plc (LSE:HSBA) acted as financial advisor to ALPEK.
ALPEK, S.A.B. de C.V. (BMV:ALPEK A) completed the acquisition of OCTAL Holding SAOC from bank muscat SAOG (MSM:BKMB) and others on May 31, 2022. Reported Earnings • Apr 28
First quarter 2022 earnings released: EPS: Mex$2.23 (vs Mex$1.16 in 1Q 2021) First quarter 2022 results: EPS: Mex$2.23 (up from Mex$1.16 in 1Q 2021). Revenue: Mex$47.9b (up 46% from 1Q 2021). Net income: Mex$4.70b (up 92% from 1Q 2021). Profit margin: 9.8% (up from 7.5% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to stay flat compared to a 10% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 8 highly experienced directors. Independent Director Jaime Zabludovsky Kuper was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Apr 09
ALPEK, S.A.B. de C.V. to Report Q1, 2022 Results on Apr 25, 2022 ALPEK, S.A.B. de C.V. announced that they will report Q1, 2022 results on Apr 25, 2022 Board Change • Apr 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 8 highly experienced directors. Independent Director Jaime Zabludovsky Kuper was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Mar 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 8 highly experienced directors. Independent Director Jaime Zabludovsky Kuper was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 17
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: Mex$3.67 (up from Mex$1.48 in FY 2020). Revenue: Mex$156.2b (up 37% from FY 2020). Net income: Mex$7.76b (up 148% from FY 2020). Profit margin: 5.0% (up from 2.7% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.2%. Over the next year, revenue is expected to shrink by 3.9% compared to a 6.5% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Duyuru • Feb 04
ALPEK, S.A.B. de C.V. to Report Q4, 2021 Results on Feb 15, 2022 ALPEK, S.A.B. de C.V. announced that they will report Q4, 2021 results on Feb 15, 2022 Duyuru • Feb 03
ALPEK, S.A.B. de C.V. (BMV:ALPEK A) agreed to acquire OCTAL Holding SAOC from bank muscat SAOG (MSM:BKMB) and others for $620 million. ALPEK, S.A.B. de C.V. (BMV:ALPEK A) agreed to acquire OCTAL Holding SAOC from bank muscat SAOG (MSM:BKMB) and others for $620 million on February 1, 2022. Alpek will purchase 100% of Octal’s shares for U.S. $620 million on a debt-free basis. Financing for the acquisition will be secured through cash on the Company’s balance sheet, free cash flow generated from existing businesses and dedicated bank loans. The transaction is subject to customary conditions to closing, including the approval of relevant regulatory authorities. The transaction is expected to close in the first half of 2022. The deal would have an immediately accretive and material impact on EBITDA of an estimated U.S. $135 million before synergies, based on Octal’s rolling 12-month EBITDA through September 30, 2021. J.P. Morgan acted as exclusive financial advisor to OCTAL on the transaction and Latham & Watkins LLP were legal advisors to OCTAL. Upcoming Dividend • Nov 01
Upcoming dividend of US$0.026 per share Eligible shareholders must have bought the stock before 08 November 2021. Payment date: 10 November 2021. Trailing yield: 5.4%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (3.6%). Reported Earnings • Oct 22
Third quarter 2021 earnings released: EPS Mex$1.05 (vs Mex$0.68 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: Mex$41.7b (up 42% from 3Q 2020). Net income: Mex$2.22b (up 55% from 3Q 2020). Profit margin: 5.3% (up from 4.9% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Reported Earnings • Jul 23
Second quarter 2021 earnings released: EPS Mex$1.18 (vs Mex$0.057 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: Mex$37.1b (up 35% from 2Q 2020). Net income: Mex$2.48b (up Mex$2.36b from 2Q 2020). Profit margin: 6.7% (up from 0.4% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 10% per year, which means it is performing significantly worse than earnings. Duyuru • Jun 08
ALPEK, S.A.B. de C.V. (BMV:ALPEK A) acquired PET Recycling and Pelletization Facility in Pennsylvania United States from Carbonlite Recycling LLC for $96 million. ALPEK, S.A.B. de C.V. (BMV:ALPEK A) acquired PET Recycling and Pelletization Facility in Pennsylvania United States from Carbonlite Recycling LLC for $96 million on June 7, 2021.
ALPEK, S.A.B. de C.V. (BMV:ALPEK A) completed the acquisition of PET Recycling and Pelletization Facility in Pennsylvania United States from Carbonlite Recycling LLC on June 7, 2021. Reported Earnings • Apr 24
First quarter 2021 earnings released: EPS Mex$1.16 (vs Mex$0.21 loss in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: Mex$32.8b (up 15% from 1Q 2020). Net income: Mex$2.45b (up Mex$2.91b from 1Q 2020). Profit margin: 7.5% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Upcoming Dividend • Mar 24
Upcoming dividend of US$0.06 per share Eligible shareholders must have bought the stock before 31 March 2021. Payment date: 06 April 2021. Trailing yield: 6.5%. Within top quartile of German dividend payers (3.3%). Higher than average of industry peers (3.6%). Reported Earnings • Mar 11
Full year 2020 earnings released: EPS Mex$1.48 (vs Mex$3.12 in FY 2019) The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: Mex$114.0b (down 4.8% from FY 2019). Net income: Mex$3.12b (down 53% from FY 2019). Profit margin: 2.7% (down from 5.5% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Analyst Estimate Surprise Post Earnings • Mar 11
Revenue beats expectations Revenue exceeded analyst estimates by 3.4%. Over the next year, revenue is forecast to grow 4.9%, compared to a 5.7% growth forecast for the Chemicals industry in Germany. Analyst Estimate Surprise Post Earnings • Feb 14
Revenue beats expectations Revenue exceeded analyst estimates by 3.4%. Over the next year, revenue is forecast to grow 12%, compared to a 5.1% growth forecast for the Chemicals industry in Germany. Reported Earnings • Feb 13
Full year 2020 earnings released The company reported a poor full year result with weaker earnings, revenues and profit margins. Full year 2020 results: Revenue: Mex$114.0b (down 4.8% from FY 2019). Net income: Mex$3.12b (down 53% from FY 2019). Profit margin: 2.7% (down from 5.5% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Duyuru • Jan 30
ALPEK, S.A.B. de C.V. to Report Q4, 2020 Results on Feb 16, 2021 ALPEK, S.A.B. de C.V. announced that they will report Q4, 2020 results on Feb 16, 2021 Is New 90 Day High Low • Jan 07
New 90-day high: €0.74 The company is up 14% from its price of €0.66 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.89 per share. Is New 90 Day High Low • Nov 20
New 90-day high: €0.68 The company is up 4.0% from its price of €0.66 on 21 August 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.82 per share. Analyst Estimate Surprise Post Earnings • Oct 24
Third-quarter earnings released: Revenue beats expectations Third-quarter revenue exceeded analyst estimates by 0.1% at Mex$29.3b. Revenue is forecast to grow 8.4% over the next year, while the growth in Chemicals industry in Germany is expected to stay flat. Reported Earnings • Oct 24
Third quarter earnings released Over the last 12 months the company has reported total profits of Mex$5.15b, down 50% from the prior year. Total revenue was Mex$112.4b over the last 12 months, down 12% from the prior year. Duyuru • Oct 20
ALPEK, S.A.B. de C.V. (BMV:ALPEK A) agreed to acquire Expandable Styrenics Business from NOVA Chemicals Corporation. ALPEK, S.A.B. de C.V. (BMV:ALPEK A) agreed to acquire Expandable Styrenics Business from NOVA Chemicals Corporation on October 19, 2020. NOVA Chemicals’ expandable styrenics business consists of two product lines, expandable polystyrene and ARCEL® resin, with manufacturing facilities in Pennsylvania and Ohio, along with commercial operations in Asia. The transaction is expected to close in fourth quarter of 2020. Duyuru • Oct 06
ALPEK, S.A.B. de C.V. to Report Q3, 2020 Results on Oct 21, 2020 ALPEK, S.A.B. de C.V. announced that they will report Q3, 2020 results on Oct 21, 2020 Is New 90 Day High Low • Sep 19
New 90-day low: €0.60 The company is down 8.0% from its price of €0.65 on 19 June 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.73 per share. 
